One Step Forward for Serelaxin as a Promising Therapy in Cardiac Fibrosis-Reference-Cited by-同舟云学术

One Step Forward for Serelaxin as a Promising Therapy in Cardiac Fibrosis

Published:2014-08 Issue:2 Volume:64 Page:229-230
ISSN:0194-911X
Container-title:Hypertension
language:en
Short-container-title:Hypertension

Author:

Fernández-Alfonso María S.¹,Ruilope Luis Miguel¹

Affiliation:

1. From the Instituto Pluridisciplinar and Facultad de Farmacia, Universidad Complutense de Madrid, Madrid, Spain (M.S.F.-A.); and Unidad de Hipertensión, Instituto de Investigación, Hospital 12 de Octubre, Madrid, Spain (L.M.R.).

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Internal Medicine

Link

https://www.ahajournals.org/doi/pdf/10.1161/HYPERTENSIONAHA.114.03642

Reference9 articles.

1. New Targets to Treat the Structural Remodeling of the Myocardium

2. Cardiovascular effects of relaxin: from basic science to clinical therapy

3. Effect of Serelaxin on Cardiac, Renal, and Hepatic Biomarkers in the Relaxin in Acute Heart Failure (RELAX-AHF) Development Program

4. Serelaxin Is a More Efficacious Antifibrotic Than Enalapril in an Experimental Model of Heart Disease

5. The role of TGF-β signaling in myocardial infarction and cardiac remodeling

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. 细胞因子受体样因子1(CRLF1)通过ERK1/2信号通路促进心脏纤维化;Journal of Zhejiang University-SCIENCE B;2023-08

2. Relaxin alleviates TGFβ1-induced cardiac fibrosis via inhibition of Stat3-dependent autophagy;Biochemical and Biophysical Research Communications;2017-12

3. Identification of porcine relaxin in plasma by liquid chromatography-high resolution mass spectrometry;Drug Testing and Analysis;2016-12-28

4. Noncoding RNA in cardiac fibrosis;International Journal of Cardiology;2015-05